Bwolfy, I am with you. I separated out and bolded
Post# of 154873
(Total Views: 406)
Posted On: 02/01/2020 11:59:02 AM
Re: bwolfy2002 #16546
Bwolfy, I am with you. I separated out and bolded 3 mTNBC and finally one IND (MIL). So not sure how NP can say in email two mTNBC and one MBC when PR says differently. This really needs to cleared up with another PR and or interview from NP, its ridiculous if PR is incorrect when such an important finding is at stake. Bruce Patterson says previous patients so that means two! That tells me 2 previous from this third, then that leaves MBC the MIL
New data from the first patient enrolled in the Company’s mTNBC Phase 1b/2 trial showed no detectable levels of circulating tumor cells (CTC) with leronlimab in combination with carboplatin at 16 weeks of treatment. In addition, this patient experienced significant reductions in epithelial-mesenchymal transition (EMT) cells dropping to zero after five weeks with treatment and currently reports zero EMT.
New data from the second patient enrolled in the Company’s mTNBC Phase 1b/2 trial showed no detectable levels of CTC with leronlimab in combination with carboplatin after two weeks of treatment. This patient also showed a 70% reduction in EMT cells after just two weeks of treatment.
Initial data from the third patient in the mTNBC trial indicated the CTC dropped to zero after two weeks of treatment with leronlimab. “Remarkably, the new patient enrolled in the clinical trial showed a significant drop in CTC and a reduction of EMT cells, the putative metastatic cells from 7 per 4mL of blood to two cells in just two weeks of treatment with leronlimab in combination with carboplatin,” said Bruce Patterson, M.D., chief executive officer and founder of IncellDx, a diagnostic partner and an advisor to CytoDyn. “The rapid response to the treatment in a pattern that is identical to previous patients is equally as remarkable and supports a predictable method of action for this drug.
MBC - MIL
New findings from the patient enrolled through an emergency investigational new drug (IND) with stage 4 HER2+ MBC that has metastasized to the liver, lung and brain, demonstrate no new metastasis in the brain after treatment with leronlimab as the only product for the metastasis to her brain. Prior to enrolling in the trial, the patient had 18 identifiable tumor spots in the brain. Today, following two months of weekly 700 mg doses of leronlimab, there are only three identifiable lesions, as seen in an MRI. This patient’s radiologist cancelled the suggested new round of radiation due to results that he believes is due only to leronlimab.
New data from the first patient enrolled in the Company’s mTNBC Phase 1b/2 trial showed no detectable levels of circulating tumor cells (CTC) with leronlimab in combination with carboplatin at 16 weeks of treatment. In addition, this patient experienced significant reductions in epithelial-mesenchymal transition (EMT) cells dropping to zero after five weeks with treatment and currently reports zero EMT.
New data from the second patient enrolled in the Company’s mTNBC Phase 1b/2 trial showed no detectable levels of CTC with leronlimab in combination with carboplatin after two weeks of treatment. This patient also showed a 70% reduction in EMT cells after just two weeks of treatment.
Initial data from the third patient in the mTNBC trial indicated the CTC dropped to zero after two weeks of treatment with leronlimab. “Remarkably, the new patient enrolled in the clinical trial showed a significant drop in CTC and a reduction of EMT cells, the putative metastatic cells from 7 per 4mL of blood to two cells in just two weeks of treatment with leronlimab in combination with carboplatin,” said Bruce Patterson, M.D., chief executive officer and founder of IncellDx, a diagnostic partner and an advisor to CytoDyn. “The rapid response to the treatment in a pattern that is identical to previous patients is equally as remarkable and supports a predictable method of action for this drug.
MBC - MIL
New findings from the patient enrolled through an emergency investigational new drug (IND) with stage 4 HER2+ MBC that has metastasized to the liver, lung and brain, demonstrate no new metastasis in the brain after treatment with leronlimab as the only product for the metastasis to her brain. Prior to enrolling in the trial, the patient had 18 identifiable tumor spots in the brain. Today, following two months of weekly 700 mg doses of leronlimab, there are only three identifiable lesions, as seen in an MRI. This patient’s radiologist cancelled the suggested new round of radiation due to results that he believes is due only to leronlimab.
(2)
(0)